Sid E O'Bryant1, Guanghua Xiao2, Fan Zhang3, Melissa Edwards4, Dwight C German5, Xiangling Yin6, Tori Como1, Joan Reisch2, Ryan M Huebinger7, Neill Graff-Radford8, Dennis Dickson9, Robert Barber10, James Hall11, Padraig O'Suilleabhain12, Paula Grammas6. 1. Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA. 2. Department of Clinical Science, UT Southwestern Medical School, Dallas, TX, USA. 3. Department of Academic and Institutional Resources and Technology, University of North Texas Health Science Center, Fort Worth, TX, USA. 4. Department of Psychology, University of North Texas, Denton, TX, USA. 5. Department of Psychiatry, UT Southwestern Medical School, Dallas, TX, USA. 6. Garrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, TX, USA. 7. Department of Surgery, UT Southwestern Medical School, Dallas, TX, USA. 8. Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, USA. 9. Department of Neuro-Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, USA Laboratory Medicine and Pathology, Mayo Clinic Jacksonville, Jacksonville, FL, USA. 10. Institute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA. 11. Institute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA Department of Psychiatry, University of North Texas Health Science Center, Fort Worth, TX, USA. 12. Department of Neurology and Neurotherapeutics, UT Southwestern Medical School, Dallas, TX, USA.
Abstract
BACKGROUND: There is a significant need for rapid and cost-effective biomarkers of Alzheimer's disease (AD) for advancement of clinical practice and therapeutic trials. OBJECTIVE: The aim of the current study was to cross-validate our previously published serum-based algorithm on an independent assay platform as well as validate across tissues and species. Preliminary analyses were conducted to examine the utility in distinguishing AD from non-AD neurological disease (Parkinson's disease, PD). METHODS: Serum proteins from our previously published algorithm were quantified from 150 AD cases and 150 controls on the Meso Scale Discovery (MSD) platform. Serum samples were analyzed from 49 PD cases and compared to a random sample of 51 AD cases and 62 controls. Support vector machines (SVM) were used to discriminate PD versus AD versus controls. Human and AD mouse model microvessel images were quantified with HAMAMATSU imaging software. Mouse serum biomarkers were assayed via MSD. RESULTS: Analysis of 21 serum proteins from 150 AD cases and 150 controls yielded an algorithm with sensitivity and specificity of 0.90 for correctly classifying AD. This multi-marker approach was then validated across species and tissue. Assay of the top proteins in human and AD mouse model brain microvessels correctly classified 90-100% of the samples. SVM analyses were highly accurate at distinguishing PD versus AD versus controls. CONCLUSIONS: This serum-based biomarker panel should be tested in a community-based setting to determine its utility as a first-line screen for AD and non-AD neurological diseases for primary care providers.
BACKGROUND: There is a significant need for rapid and cost-effective biomarkers of Alzheimer's disease (AD) for advancement of clinical practice and therapeutic trials. OBJECTIVE: The aim of the current study was to cross-validate our previously published serum-based algorithm on an independent assay platform as well as validate across tissues and species. Preliminary analyses were conducted to examine the utility in distinguishing AD from non-AD neurological disease (Parkinson's disease, PD). METHODS: Serum proteins from our previously published algorithm were quantified from 150 AD cases and 150 controls on the Meso Scale Discovery (MSD) platform. Serum samples were analyzed from 49 PD cases and compared to a random sample of 51 AD cases and 62 controls. Support vector machines (SVM) were used to discriminate PD versus AD versus controls. Human and ADmouse model microvessel images were quantified with HAMAMATSU imaging software. Mouse serum biomarkers were assayed via MSD. RESULTS: Analysis of 21 serum proteins from 150 AD cases and 150 controls yielded an algorithm with sensitivity and specificity of 0.90 for correctly classifying AD. This multi-marker approach was then validated across species and tissue. Assay of the top proteins in human and ADmouse model brain microvessels correctly classified 90-100% of the samples. SVM analyses were highly accurate at distinguishing PD versus AD versus controls. CONCLUSIONS: This serum-based biomarker panel should be tested in a community-based setting to determine its utility as a first-line screen for AD and non-AD neurological diseases for primary care providers.
Authors: Sid E O'Bryant; Guanghua Xiao; Robert Barber; Joan Reisch; Rachelle Doody; Thomas Fairchild; Perrie Adams; Steven Waring; Ramon Diaz-Arrastia Journal: Arch Neurol Date: 2010-09
Authors: Christoph Laske; Thomas Leyhe; Elke Stransky; Nadine Hoffmann; Andreas J Fallgatter; Janko Dietzsch Journal: Int J Neuropsychopharmacol Date: 2011-04-05 Impact factor: 5.176
Authors: Maria Z Kounnas; Anne M Danks; Soan Cheng; Curtis Tyree; Elizabeth Ackerman; Xulun Zhang; Kwangwook Ahn; Phuong Nguyen; Dan Comer; Long Mao; Chengzhi Yu; David Pleynet; Paul J Digregorio; Gonul Velicelebi; Kenneth A Stauderman; William T Comer; William C Mobley; Yue-Ming Li; Sangram S Sisodia; Rudolph E Tanzi; Steven L Wagner Journal: Neuron Date: 2010-09-09 Impact factor: 17.173
Authors: Holly D Soares; Yu Chen; Marwin Sabbagh; Alex Roher; Alex Rohrer; Elisabeth Schrijvers; Monique Breteler Journal: Ann N Y Acad Sci Date: 2009-10 Impact factor: 5.691
Authors: E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel Journal: J Prev Alzheimers Dis Date: 2014-12
Authors: Sid E O'Bryant; Fan Zhang; Leigh A Johnson; James Hall; Melissa Edwards; Paula Grammas; Esther Oh; Constantine G Lyketsos; Robert A Rissman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: H Hampel; S E O'Bryant; J I Castrillo; C Ritchie; K Rojkova; K Broich; N Benda; R Nisticò; R A Frank; B Dubois; V Escott-Price; S Lista Journal: J Prev Alzheimers Dis Date: 2016-09-06
Authors: Sid E O'Bryant; Michelle M Mielke; Robert A Rissman; Simone Lista; Hugo Vanderstichele; Henrik Zetterberg; Piotr Lewczuk; Holly Posner; James Hall; Leigh Johnson; Yiu-Lian Fong; Johan Luthman; Andreas Jeromin; Richard Batrla-Utermann; Alcibiades Villarreal; Gabrielle Britton; Peter J Snyder; Kim Henriksen; Paula Grammas; Veer Gupta; Ralph Martins; Harald Hampel Journal: Alzheimers Dement Date: 2016-11-18 Impact factor: 21.566
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Harald Hampel; Sid E O'Bryant; José L Molinuevo; Henrik Zetterberg; Colin L Masters; Simone Lista; Steven J Kiddle; Richard Batrla; Kaj Blennow Journal: Nat Rev Neurol Date: 2018-11 Impact factor: 42.937